ZLDI-8

N/A

Report date: 2022/01/05 15:24:33
NME

Base Information

Drug NameZLDI-8
Drug Alias NameZLDI-8
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDisintegrin and metalloproteinase domain-containing protein 17 inhibitors
TargetsDisintegrin and metalloproteinase domain-containing protein 17
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShenyang Pharmaceutical University
China Registration ClassN/A

Develop Information

Active CompaniesShenyang Pharmaceutical University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A